文献速递淋巴瘤

早期滤泡性淋巴瘤外周血与骨髓中BCL2/IGH基因重排的RQ-PCR与微滴数字PCR比较分析

Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
PubMed 文献 · Br J Haematol · 2017-04-17

在67例I/II期滤泡性淋巴瘤患者的外周血和骨髓配对样本中,比较RQ-PCR与ddPCR检测BCL2/IGH重排。ddPCR与RQ-PCR总体一致率为81.9%(113/138),在可定量病例中一致率为97.5%。ddPCR在基线可恢复44.4%定性PCR阴性样本的MBR+标记,且仅ddPCR定量的肿瘤负荷可显著预测无进展生存。

要点

  • ddPCR与RQ-PCR总体一致率81.9%,可定量病例中一致率97.5%。
  • 基线时ddPCR在8/18(44.4%)定性PCR阴性样本中恢复MBR+标记。
  • 仅ddPCR定量的肿瘤负荷可显著预测无进展生存。

核心结论

  • 在局限性滤泡性淋巴瘤中,ddPCR是监测微小残留病的有前景工具,至少与RQ-PCR相当且可能更准确。
  • 外周血是连续进行BCL2/IGH微小残留病评估的合适来源,无论采用何种方法。

研究设计与样本

  • 对67例I/II期滤泡性淋巴瘤患者诊断时的配对 peripheral blood(PB)和 bone marrow(BM)样本进行BCL2/IGH重排分析。
  • 对诊断时主要断裂点区域阳性(MBR+)的病例,在局部放疗和利妥昔单抗给药后行RQ-PCR和ddPCR检测。

主要发现

  • ddPCR与RQ-PCR总体一致率为81.9%(113/138样本),在40/138可定量疾病(RQ-PCR≥10^-5)样本中一致率为97.5%。
  • 基线时ddPCR在8/18(44.4%)定性PCR检测为MBR阴性/次要簇区域阴性/次要BCL2阴性的样本中恢复MBR+标记。
  • 诊断时肿瘤负荷仅在ddPCR定量时显著预测无进展生存。
  • 配对PB和BM样本分析显示定性和定量方法检测BCL2/IGH+细胞高度一致;ddPCR阳性40/62样本(25 PB+/BM+;9 PB+/BM-;6 PB-/BM+),其中34/40(85%)仅通过PB研究识别。

临床怎么用

  • 作者认为,在局限性滤泡性淋巴瘤中,ddPCR是监测微小残留病的有前景工具,至少与RQ-PCR相当且可能更准确。
  • 作者认为,外周血是连续进行BCL2/IGH微小残留病评估的合适来源,无论采用何种方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BCL2/IGH rearrangements were analysed by polymerase chain reaction (PCR) at diagnosis in paired peripheral blood (PB) and bone marrow (BM) samples from 67 patients with stage I/II follicular lymphoma (FL). Real time quantitative PCR (RQ-PCR) and digital droplet PCR (ddPCR) were performed in cases with a major breakpoint region (MBR+) at diagnosis and after localized radiotherapy and rituximab administration in order to investigate the applicability of ddPCR. The overall ddPCR/RQ-PCR concordance was 81·9% (113/138 samples) and 97·5% in the 40/138 with quantifiable disease (RQ-PCR≥10-5 ). At baseline, ddPCR allowed the recovery of a MBR+ marker in 8/18 (44·4%) samples that resulted MBR-negative/minor cluster region-negative/minor BCL2-negative by qualitative PCR. Moreover, the tumour burden at diagnosis significantly predicted progression-free survival (PSF) only when quantified by ddPCR. Paired PB and BM samples analysis demonstrated a high concordance in the detection of BCL2/IGH+ cells by qualitative and quantitative methods; in particular, 40/62 samples were positive by ddPCR (25 PB+/BM+; 9 PB+/BM-; 6 PB-/BM+), with 34/40 (85%) identified by the study of PB only. In conclusion, in localized FL, ddPCR is a promising tool for monitoring minimal residual disease (MRD) that is at least comparable to RQ-PCR and potentially more accurate. PB is a suitable source for serial BCL2/IGH MRD assessments, regardless of the methodology utilized.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cavalli M, De Novi LA, Della Starza I, et al. Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. Br J Haematol. 2017. PMID: 28419517. doi:10.1111/bjh.14616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。